Search results
Added:
3 years ago
Atherosclerotic cardiovascular disease (CVD) is a global epidemic. As life expectancy has increased, chronic degenerative diseases have become a significant healthcare burden, affecting developed and developing countries alike,1 with atherosclerotic disease the leading cause of death according to the WHO.2 The development of effective strategies for the prevention of cardiovascular events at…
View more
Added:
3 years ago
Cardiovascular disease (CVD) is the leading cause of mortality in the world, accounting for 17.9 million deaths per year and 31% of deaths worldwide.1 In addition to the toll on human life, the healthcare cost of CVD continues to grow, with estimates of up to US$1.1 trillion by 2035.1 Given the significant public health burden of disease as well as the cost of healthcare, we must shift our focus…
View more
Added:
3 years ago
The concentration of plasma low-density lipoprotein cholesterol (LDL-C) is reduced, while that of total high-density lipoprotein cholesterol (HDL-C) is increased, following inhibition of cholesteryl ester transfer protein (CETP). This combined effect has made inhibition of CETP an attractive pharmacological approach for reducing the residual incidence of cardiovascular disease (CVD) remaining…
View more
Added:
3 years ago
Pharmacological regulation of lipid metabolism in patients with dyslipidaemia is undeniably associated with significant reductions in risk of cardiovascular (CV) morbidity and mortality. There are strong clinical trial data to support the use of lipid-lowering therapies in the settings of both primary and secondary prevention. Statins and fibrates are two classes of drug that have demonstrated…
View more
Added:
2 years ago
What are the lipid highlights from ACC.22?
In this insightful review, Dr Erin Michos (Johns Hopkins University School of Medicine, Baltimore, MD, US) talks about selected ACC.22 late-breaking clinical trials highlighting the take-home messages for clinical practice.
Trials covered in detail include:
00:28: APOLLO Trial: Magnitude and Duration of Effects of a Short-interfering RNA Targeting…
View more
Added:
1 week ago
ACC.24 — Dr Brian Bergmark (Brigham and Women's Hospital, Harvard Medical School, US) joins us in this interview to discuss the findings of a study into olezarsen, previously known as AKCEA-APOCIII-LRx, in patients with hypertriglyceridemia and atherosclerotic cardiovascular disease (ASCVD), with or without severe hypertriglyceridemia (NCT05355402).This multicenter, randomized, double-blind study…
View more
Added:
12 months ago
Added:
3 years ago
We are witnessing an epidemic global increase in the prevalence of obesity and its clinical consequences (e.g. insulin resistance and diabetes). This epidemic has been potentiated and sustained by the widespread adoption of unhealthy lifestyles in broad swathes of the population and is characterised by a sedentary lifestyle and an imbalance between the type and characteristics of nutrition,…
View more
Foreword
Added:
3 years ago
Article
Added:
2 years ago
In this short interview from our coverage of the ACC.22 late-breaking trials, Dr Brian Bergmark (Brigham and Women's Hospital, Harvard Medical School, US) discusses the data from the TRANSLATE-TIMI 70 study; a phase 2b, randomised trial of vupanorsen (an antisense oligonucleotide)(NCT04516291).
The primary objective was to evaluate the effect of vupanorsen on non-high-density lipoprotein (non-HDL…
View more
